philip worboys  theravance  inc  zoominfocom insider trading  worboys philip d  form  sec filings home  archives  products  about  contact  faq  new user sign up  sign in form  filings insider buys significant buys penny stocksinsider buying insider sales insider buy sell ratios stock options insider tradingstock screener insider tradinggraph view insider watch sec filings insider trading  worboys philip d select time period  month  months  months  months  year  years  years  years all data       google     yahoo send this page to   blog    digg    reddit    facebook    stumble    delicious enter stock ticker symbol or cik cik lookup search by company or insider name insiders might sell their shares for any number of reasons but they buy them for only one they think the price will rise  peter lynch  what is insider trading email a friend  historical filings delayed by  months new user sign up for real time data existing user sign in stock options exercise award grant conversion transactiondate reporteddate exercisableexpiration company symnbol insiderrelationship sharestraded conversionprice sharesowned filing tax withholding  pm nana theravance biopharma inc tbph worboys philip dsvp translational science   direct view tax withholding  pm nana theravance biopharma inc tbph worboys philip dsvp translational science   direct view tax withholding  pm nana theravance biopharma inc tbph worboys philip dsvp translational science   direct view option award  pm nana theravance biopharma inc tbph worboys philip dsvp translational science   direct view   secformcom all rights reserved archives        sat  jul    sec is the us securities and exchange commission edgar is a trademark of the sec secformcom is not affiliated with or approved by the us securities and exchange commission sec terms of use  privacy statement    compensation information for philip d worboys  senior vice president translational science of theravance biopharma inc  salarycom enterprise small business personal contact us log in salaries jobs education advice philip d worboys executive compensation as senior vice president translational science at theravance biopharma inc philip d worboys made  in total compensation of this total  was received as a salary  was received as a bonus  was received in stock options  was awarded as stock and  came from other types of compensation this information is according to proxy statements filed for the  fiscal year enter an executive or company name new search go the chart on this page features a breakdown of the total annual pay for philip d worboys  senior vice president translational science at theravance biopharma inc as reported in their proxy statements total cash compensation information is comprised of yearly base pay and bonuses theravance biopharma inc income statements for executive base pay and bonus are filed yearly with the sec in the edgar filing system theravance biopharma inc annual reports of executive compensation and pay are most commonly found in the def a documents total equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year other compensation covers all compensationlike awards that dont fit in any of these other standard categories numbers reported do not include change in pension value and nonqualified deferred compensation earnings other executives at this company bradford j shafer rick e winningham renee d gala sharathchandra sharath s hegde philip d worboys base pay bonus  incentive comp total cash compensation stock award value option award value total equity total other total compensation browse executives by first name a b c d e f g h i j k l m n o p q r s t u v w x y z browse companies by company name a b c d e f g h i j k l m n o p q r s t u v w x y z  this report is not for commercial use thorough reviews have been conducted to assure this data accurately reflects disclosures however for a complete and definitive understanding of the pay practices of any company users should refer directly to the actual complete proxy statement use of data  disclaimer the information shown here is a reporting of information included in the companys proxy statement the proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information for those interested in conducting a detailed compensation analysis we recommend that you review the entire proxy statement you may retrieve the full proxy statement by going to the securities and exchange commission sec website at wwwsecgov and entering the companys name and then looking in the first column for an entry of form def a or any similar code you may also find the annual proxy statement by going directly to the companys website what is a proxy statement a proxy statement or proxy is a form that every publicly traded us company is required to file with the us securities  exchange commission sec within  days after the end of its fiscal year the proxy must be sent to every shareholder in advance of the companys annual shareholders meeting all proxy statements are public filings made available to the general public by the sec the proxy statements main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting including decisions such as electing directors ratifying the selection of auditors and other shareholderrelated decisions including shareholderinitiated initiatives also proxies must disclose specific detailed information regarding the pay practices for certain executives       privacy policy terms of use about us contact us  salarycom all rights reserved us salaries canadian salaries purchase a salary report salaries by category salaries by income salaries by industry popular salaries negotiation tips benefits calculator search job openings job openings by state job openings by category education by career education by level education by major cost of living calculator philip d worboys  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors philip d worboys check out list of companies and businesses related to philip d worboys find out philip d worboys address and contact details view other people related to philip d worboys  coworkers colleagues companions etc address co theravance biopharma us inc  gateway boulevard south san francisco  ca companies related to philip d worboys cikcompany namepositioncompany addresstheravance biopharma incsvp translational science ugland house south church street george town grand cayman ky philip d worboys on the web persons related to philip d worboys  theravance biopharma incnamepositioncitymichael g atiehdirector south san franciscoleonard m blumsr vp chief comm officer bothellleonard m blumsr vp chief comm officer south san franciscoeran broshydirector branforderan broshydirector south san franciscohenrietta foredirector south san franciscohenrietta foredirector south san franciscorenee d galasvp chief financial officer south san franciscoplc glaxosmithkline owner brentford middlesexrobert v gunderson jrdirector menlo parkrobert v gunderson jrdirector redwood citybrett k haumannsvp clin dev  chief med ofc south san franciscosharathchandra s hegdesvp research south san franciscojeffrey david jonkersenior vp corp  bus dev south san franciscojunning leesr vp technical operations south san franciscojunning leesr vp technical operations south san franciscoburton g malkieldirector princetonburton g malkieldirector south san franciscomathai mammensvp research  development south san franciscomathai mammensvp research  development south san franciscodean j mitchelldirector plainsborodean j mitchelldirector south san franciscosusan molineauxdirector menlo parkdonal oconnordirector alleganfrank pasqualonesvp chief comm ops officer south san franciscofrank pasqualonesr vp operations south san franciscokenneth r pitzersvp prod strat  comm plng south san franciscopeter s ringrosedirector south san franciscopeter s ringrosedirector south san franciscobradford j shaferevp gen counsel secretary south san franciscobradford j shafersr vp gen counsel secretary south san franciscotheravance inc owner south san franciscogeorge m whitesidesdirector cambridgegeorge m whitesidesdirector south san franciscorick e winninghamchief executive officer south san franciscorick e winninghamchief executive officer south san franciscophilip d worboyssvp translational science south san franciscowilliam d youngdirector south san franciscowilliam d youngdirector south san francisco theravance biopharma inc tbpho people  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states theravance biopharma inc tbpho related topics stocksstock screenermarket datahealthcarepharmaceuticals overview news key developments people charts financials analysts research pulse tbpho on consolidated issue listed on nasdaq global market usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  summary name age since current position rick winningham  chairman of the board chief executive officer renee gala   senior vice president chief financial officer treasurer bradford shafer   executive vice president general counsel secretary brett haumann   senior vice president  clinical development and chief medical officer sharathchandra hegde   senior vice president research frank pasqualone   senior vice president and chief commercial operations officer kenneth pitzer   senior vice president  product strategy and commercial planning philip worboys   senior vice president translational science william young   lead independent director eran broshy   independent director henrietta fore   independent director robert gunderson   independent director burton malkiel   independent director dean mitchell   independent director susan molineaux   independent director donal oconnor   independent director peter ringrose   independent director george whitesides   independent director » insider trading biographies name description rick winningham mr rick e winningham serves as the chairman of the board chief executive officer of the company from october  to august  mr winningham served as chief executive officer of innoviva where he also served as chairman of the board of directors from april  to october  from  to  he served as president bristolmyers squibb oncologyimmunologyoncology therapeutics network otn and also as president of global marketing from  to  in addition to operating responsibility for us oncologyimmunologyotn at bristolmyers squibb bms mr winningham also had full responsibility for global marketing in the cardiovascular infectious disease immunology oncologymetabolics and gugineuroscience therapeutic areas over a fifteenyear period beginning in  with bms and its predecessor bristolmyers mr winningham held various us and global management positions mr winningham is a member of biotechnology industry organizations board of directors and serves on the health section governing board standing committee on reimbursement mr winningham served as a director on the board of directors of the california healthcare institute chi from november  to march  he was elected chairman of chi in january  a position he held until chi merged with baybio to become the california life sciences association clsa in march  mr winningham was subsequently elected to the role of chairman of clsa in march  he stepped down from the clsa position in november  he is a member of the board of directors of jazz pharmaceuticals plc and of oncomed pharmaceuticals inc mr winningham holds an mba from texas christian university and a bs degree from southern illinois university we believe that it is appropriate and desirable for our chief executive officer to serve on our board of directors mr winninghams demonstrated leadership in his field his prior senior management experience in our industry and his experience as our chief executive officer contrib renee gala ms renee d gala serves as senior vice president chief financial officer treasurer of the company ms gala joined theravance biopharma as vice president finance and treasurer in june  in connection with our spinoff from innoviva inc innoviva known as theravance inc prior to january   became senior vice president finance in july  and became senior vice president and chief financial officer in december  prior to the spinoff ms gala had been vice president finance at innoviva since january  ms gala joined innoviva in june  initially as director of financial planning and analysis and then as senior director of finance and procurement in july  from  to  ms gala worked at eli lilly and company where she held positions of increasing responsibility in global treasury pharmaceutical sales and corporate strategybusiness development prior to joining eli lilly she spent seven years in the energy industry in the us and internationally in positions focused on corporate finance project finance and mergers and acquisitions she is a member of the board of directors of corcept therapeutics incorporated ms gala earned a bs in mathematics from vanderbilt university and an mba from columbia business school bradford shafer mr bradford j shafer esq jd serves as executive vice president general counsel and secretary of the company previously he was our senior vice president general counsel since september  prior to joining theravance biopharma mr shafer served as senior vice president general counsel and secretary at innoviva since august  from  to  he served as general counsel of heartport inc a medical device company from  to  mr shafer was a partner in the business and technology group at the law firm of brobeck phleger  harrison llp mr shafer holds a jd from the university of california hastings college of the law where he was editorinchief of the hastings constitutional law quarterly and a ba from the university of the pacific where he graduated magna cum laude brett haumann dr brett k haumann md is senior vice president  clinical development and chief medical officer of the company he joined theravance biopharma in june  in connection with our spinoff from innoviva after joining innoviva as vice president clinical development in october  he became vice president clinical development and operations of innoviva in march  and became senior vice president clinical development at theravance biopharma in december  prior to joining innoviva dr haumann served as chief medical officer at and on the board of directors of circassia limited a biopharmaceutical company previously dr haumann held senior positions at glaxosmithkline including medicines development leader and vice president clinical development dr haumann has more than  years of experience in the discovery and development of pulmonary and allergy medicines dr haumann completed his md at the university of witwatersrand medical school south africa and holds an mba from open university united kingdom sharathchandra hegde dr sharathchandra s hegde phd is senior vice president  research of the company dr hegde joined theravance biopharma in june  in connection with the spinoff from innoviva and became senior vice president research in march  after joining innoviva in september  dr hegde held various positions in the pharmacology department before being promoted to vice president pharmacology in june  and later becoming vice president discovery biology of theravance biopharma in june  prior to joining innoviva dr hegde spent  years at syntex corporation later acquired by roche holdings ltd as an associate director and later director of pharmacology dr hegde obtained his phd in pharmacology from the university of houston and obtained his bpharmmpharm degree in pharmacypharmacology from the university of bombay frank pasqualone mr frank pasqualone serves as senior vice president and chief commercial operations officer of the company he joined theravance biopharma as senior vice president operations in june  in connection with our spinoff from innoviva prior to the spinoff mr pasqualone held the position of senior vice president operations at innoviva since january  from  to  he served as president of intercontinental region latin america middle east and africa and also as president of southern europe from  to  at bristolmyers squibb bms over a year period with bms mr pasqualone held senior management positions in the us and globally in the us he was responsible for the oncologyvirology business and led the marketing group in the diabetes business since leaving bristolmyers squibb and prior to joining theravance mr pasqualone was selfemployed as a parttime consultant mr pasqualone holds an mba from university of dayton and a bs in marketing from bowling green state university in ohio kenneth pitzer dr kenneth r pitzer dvm serves as senior vice president  product strategy and commercial planning of the company previously dr pitzer was vice president strategic and commercial planning since he joined theravance biopharma in october  from innoviva where he held the position of vice president strategic and commercial planning since january  dr pitzer joined innoviva in  as director new product planning and held various positions in the commercial development department before being promoted to vice president strategic and commercial planning in january  prior to joining innoviva dr pitzer worked at lederle laboratories a pharmaceutical manufacturing company as marketing manager from  to  and then at cygnus inc a biopharmaceutical company from  until  ultimately serving as the vice president of product management dr pitzer earned a doctor of veterinary medicine degree from the ohio state university in  and an mba from carnegiemellon university in  philip worboys dr philip d worboys phd serves as senior vice president translational science of the company dr worboys has served as our senior vice president translational science since march  where is he responsible for leading the progression of drug candidates from the discovery stage into human clinical studies including clinical pharmacology and biomarker development as well as project management previously dr worboys was vice president drug metabolism and pharmacokinetics dmpk since he joined theravance biopharma in october  from innoviva where he held the position of vice president dmpk since november  prior to joining innoviva he served as senior director dmpk at roche bioscience inc since  dr worboys was an associate director dmpk at pharmacia corporation from  until its acquisition by pfizer inc and was senior director dmpk at pfizer inc from  to  he spent the first part of his career in dmpk at merck sharp  dohme in harlow united kingdom and worked in various capacities at aventis unilever and glaxosmithkline prior to that dr worboys obtained his phd degree in pharmaceutics from manchester university united kingdom he holds a bsc degree in biochemistry from imperial college of science technology  medicine at the university of london william young mr william d young serves as the lead independent director of the company prior to our spinoff from innoviva in june  and since april  mr young served as a director of innoviva he has been a venture partner at clarus ventures a venture capital firm and executive chairman of nanostring technologies a biotechnology company and clarus portfolio company since  mr young served from  until  as chairman of the board of directors and chief executive officer of monogram biosciences inc a biotechnology company from  to  mr young was employed at genentech inc most recently as chief operating officer where he was responsible for all product development manufacturing and commercial functions prior to joining genentech mr young worked at eli lilly and company for  years in addition to nanostring technologies mr young is a member of the board of directors of vertex pharmaceuticals he was a member of biomarin incs board until october  and biogen idec incs board of directors until june  having served as a director since  and as chairman of the board since  mr young received his mba from indiana university and his bs in chemical engineering from purdue university and an honorary doctorate of engineering from purdue university mr young was elected to the national academy of engineering in  for his contributions to biotechnology mr youngs demonstrated leadership in his field his understanding of our industry and his senior management experience in several companies in our industry contributed to our conclusion that he should serve as a director eran broshy mr eran broshy is an independent director of the company mr broshy has been an operating executive with tailwind capital a new york based private equity firm supporting their healthcare investment efforts since september  from march  until august  he worked with linden capital partners and court square capital both private equity firms as operating partner and executive advisor respectively and from june  until december  he worked with providence equity partners as a senior advisor supporting the private equity firms healthcare information investment efforts mr broshy previously served for over a decade as the chief executive officer until  and chairman of the board of directors until  of inventiv health inc a privately held company and until august  a nasdaq listed company that delivers a broad range of clinical and commercialization services to pharmaceutical and life sciences companies globally prior to joining inventiv mr broshy was a management consultant with the boston consulting group bcg for  years including as the partner responsible for bcgs healthcare practice across the americas he also served as president and chief executive officer of coelacanth corporation a privately held biotechnology company he currently serveson the board of directors of magellan health inc a public specialty health care management company and within the previous five years mr broshy has also served on the board of directors of inventiv health inc he also serves on the board of a number of private companies as a member of the corporation of the massachusetts institute of technology mit and on mits dean of science advisory council as well as the simon wiesenthal centers new york executive board american jewish committee ny board and the israel venture network henrietta fore ms henrietta holsman fore serves as an independent director of the company prior to our spinoff from innoviva in june  and since october  ms fore served as a director of innoviva ms fore has served as the chairman of the board and chief executive officer of holsman international company a manufacturing and investment company since  from  to  ms fore served as the administrator of the us agency for international development and director of united states foreign assistance holding the equivalent rank as deputy secretary of state in this position she was responsible for managing us foreign assistance to countries recovering from disaster trying to escape poverty and enaging in democratic reforms she also served on the boards of the overseas private investment corporation and the millennium challenge corporation during this period from  to  ms fore served as under secretary of state for management the chief operating officer for the department of state where she was responsible for the people resources facilities technology and security of the department and was the secretarys principal advisor on management issues ms fore serves on the corporate boards of exxon mobil corporation general mills inc and essilor international group se is global cochair of the asia society and a trustee of the aspen institute and the center for strategic and international studies csis she also serves on the boards of the committee encouraging corporate philanthropy center for global development and initiative for global development and chairs the middle east investment initiative ms fore has a ba degree in history from wellesley college and a ms degree in public administration from the university of northern colorado robert gunderson mr robert v gunderson jr jd serves as an independent director of the company prior to our spinoff from innoviva in june  and since september  mr gunderson served as a director of innoviva he is a founding partner of the law firm of gunderson dettmer stough villeneuve franklin  hachigian llp where he has practiced since  mr gunderson currently serves as a director of a number of private companies and served on the board of directors of vitae pharmaceuticals inc until its sale to allergan plc in october  mr gunderson is a fellow of the american college of governance counsel mr gunderson holds a jd from the university of chicago where he was executive editor of the university of chicago law review mr gunderson also received an mba in finance from the wharton school university of pennsylvania and an ma from stanford university mr gundersons demonstrated leadership in his field his understanding of our industry and his knowledge of financial and financing matters contributed to our conclusion that he should serve as a director burton malkiel dr burton g malkiel phd serves as an independent director of the company prior to our spinoff from innoviva in june  and since july  dr malkiel served as a director of innoviva dr malkiel is the chief investment officer at wealthfront inc a position he has held since november  and the chemical bank chairmans professor of economics emeritus and senior economist at princeton university a position he has held since july  following positions as a senior research economist and professor at princeton university since  dr malkiel is the author of a random walk down wall street and over  articles and is the author or coauthor of nine other books from  to  he was dean of the yale university school of management and also served as the william s beinecke professor of management studies he is a past appointee to the presidents council of economic advisors in addition dr malkiel currently serves on the board of directors of several corporations including genmab as and served on the board of directors of the vanguard group ltd until march  he also serves on several investment management boards including the investment committees for the american philosophical association and alpha shares llc he is a past president of the american finance association and the international atlantic economic association he holds a ba and mba degree from harvard university and a phd degree from princeton university dean mitchell mr dean jonathan mitchell serves as an independent director of the company mr mitchell has served as executive chairman of the board of directors of covis pharma holdings a specialty pharmaceutical company since august  chairman of paxvax corporation since january  and on the board of directors immunogen inc since  and intrexon inc since  within the past five years he also served as a director of ista pharmaceuticals inc lux biosciences inc and talecris biotherapeutics holdings corp mr mitchell served as president and chief executive officer of lux biosciences inc a biotechnology company focusing on the treatment of ophthalmic diseases from july  to august  prior to lux biosciences he served as president and chief executive officer of both alpharma inc a publicly traded specialty pharmaceutical company from  until its acquisition by king pharmaceuticals inc in  and guilford pharmaceuticals inc a publicly traded pharmaceutical company focused in oncology and acute care from  until its acquisition by mgi pharma inc in  from  to  he served in various senior executive capacities in the worldwide medicines group of bristolmyers squibb company a pharmaceutical company prior to the bristolmyers squibb company he spent  years at glaxosmithkline plc in assignments of increasing responsibility spanning sales marketing general management commercial strategy and clinical development and product strategy mr mitchell holds an mba from city university london and a bsc in biology from coventry university susan molineaux dr susan m molineaux phd is independent director of the company dr molineaux has served as president chief executive officer and as a member of the board of directors of calithera biosciences inc since she cofounded the biopharmaceutical company in march  dr molineaux cofounded proteolix inc a biopharmaceutical company where she served as chief scientific officer from  to  chief executive officer from january  to january  and again as chief scientific officer from february  until proteolixs acquisition by onyx pharmaceuticals inc in november  from  to  dr molineaux served as vice president of biology at rigel pharmaceuticals inc a drug development company from  to  she served as vice president of biology at praelux inc a biopharmaceutical company and from  through  she served as vice president of drug development at praecis pharmaceuticals inc a biopharmaceutical company from  until  she was a scientist in the immunology group at merck  co dr molineaux also serves as a member of the board of directors of geron corporation a biopharmaceutical company and served as a member of the board of directors of the california life sciences association until march  she is a scientific advisor at lightstone ventures dr molineaux holds a bs in biology from smith college and a phd in molecular biology from johns hopkins university and she completed a postdoctoral fellowship at columbia university dr molineauxs extensive management experience in pharmaceutical drug development particularly as it relates to managing and conducting clinical trials her experience as a chief executive officer and board member of multiple biotechnology companies and her demonstrated leadership in our field contributed to our conclusion that she should serve as a director donal oconnor mr donal oconnor is independent director of the company mr oconnor is the chairman of galco steel limited and huttonread unlimited company having been appointed to their boards in september  and march  respectively and has been a nonexecutive director of perrigo company plc since november  he was a nonexecutive director of elan corporation plc from may  until it was acquired by perrigo in december  he was a nonexecutive director and senior independent director of readymix plc from december  until may  he was appointed by the irish government as chairman of anglo irish bank from december  until june  he was the irish high court appointed administrator of icarom plc from  until february  mr oconnor was a member of the board of the irish auditing and accountancy supervisory authority from its inception as an interim board in  until  he was a member of pricewaterhousecoopers pwc global board from  until  and is a former chairman of the pwc eurofirms board mr oconnor originally joined pwc in  and was appointed partner in  he was later appointed partner in charge of the pwc financial services practice in  and leader of the audit practice in  he was elected senior partner in  and was reelected in  and  he served as senior partner of pwc ireland for over twelve years until  mr oconnor obtained a bachelor of commerce degree from university college dublin and is a fellow of the institute of chartered accountants in ireland mr oconnors senior management experience and demonstrated leadership in his field his experience as a director of numerous companies including irish entities and his knowledge of financial and financing matters contributed to our conclusion that he should serve as a director peter ringrose dr peter s ringrose phd serves as an independent director of the company prior to our spinoff from innoviva inc innoviva known as theravance inc prior to january   in june  and since april  dr ringrose served as a director of innoviva dr ringrose was chief scientific officer and president of bristolmyers squibb pharmaceutical research institute from  to  and senior vice president for worldwide drug discovery at pfizer inc from  to  dr ringrose served as chair of the biotechnology and biological sciences research council uk from  to  and was a nonexecutive director of cambridge antibody technology until its acquisition by astra zeneca in  of astex therapeutics inc until its acquisition by supergen in september  and of biotica technology ltd until december  he is currently a nonexecutive director of rigel pharmaceuticals inc dr ringrose is a council member of the uk foundation for science and technology and was a member the uk governments technology strategy board until  dr ringrose received a bsc ma and phd in biochemistry from the university of cambridge his significant scientific leadership experience in the pharmaceutical industry contributed to our conclusion that dr ringrose should serve as a director george whitesides dr george m whitesides phd serves as an independent director of company prior to our spinoff from innoviva in june  and since the inception of innoviva in  dr whitesides served as a director of innoviva he has been woodford l and ann a flowers university professor at harvard university since  from  to  dr whitesides was mallinckrodt professor of chemistry at harvard university from  to  he was a member of the department of chemistry at harvard university and chairman of the department of chemistry from  to  he was a faculty member of the massachusetts institute of technology from  to  dr whitesides was a  recipient of the national medal of science he is a member of the editorial boards of  scientific journals he is also a member of the board of directors of nano terra inc arsenal biomedical inc  biomedical inc diagnostics for all inc and soft robotics inc dr whitesides holds a phd in chemistry from the california institute of technology and a ba from harvard university dr whitesides demonstrated leadership in his field his knowledge of scientific matters affecting our business and his understanding of our industry contributed to our conclusion that he should serve as a director basic compensation name fiscal year total rick winningham  renee gala  bradford shafer  brett haumann  sharathchandra hegde  frank pasqualone  kenneth pitzer  philip worboys  william young  eran broshy  henrietta fore  robert gunderson  burton malkiel  dean mitchell  susan molineaux  donal oconnor  peter ringrose  george whitesides  as of   dec  options compensation name options value rick winningham   renee gala   bradford shafer   brett haumann   sharathchandra hegde   frank pasqualone   kenneth pitzer   philip worboys   william young   eran broshy   henrietta fore   robert gunderson   burton malkiel   dean mitchell   susan molineaux   donal oconnor   peter ringrose   george whitesides   insider trading name shares traded price gala renee d   pitzer kenneth r   shafer bradford j   hegde sharathchandra s   winningham rick e   pasqualone frank   worboys philip d   haumann brett k   fore henrietta holsman   malkiel burton g   molineaux susan m   whitesides george m   ringrose peter s   broshy eran   oconnor donal   gunderson robert v jr   mitchell dean j   young william d   haumann brett k   haumann brett k   shafer bradford j   lee junning   winningham rick e   gala renee d   hegde sharathchandra s   » full list on insider trading related topics stocksstock screenermarket datahealthcarepharmaceuticals philip d worboys phd  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in philip d worboys phd senior vice president translational science at theravance biopharma inc view full profile are you philip d worboys phd claim your profile   sign up for equilar atlas and view philip d worboys phds full profile with equilar atlas you can identify corporate executives in philip d worboys phds network and community follow changes in philip d worboys phds employment and moneyinmotion connect with philip d worboys phd through your network of contacts philip d worboys phds executive work history current senior vice president translational science theravance biopharma inc past to view philip d worboys phds complete executive work history sign up now age      philip d worboys phds biography philip d worboys phd has served as our senior vice president translational science since march  where is he responsible for leading the progression of drug candidates from the discovery stage into human clinical studies including clinical pharmacology and biomarker development as well as project management previously dr worboys was vice president drug metabolism and pharmacokinetics dmpk since he joined theravance biopharma in october  from innoviva where he held the position of vice president dmpk since november  prior to joining innoviva he served as senior director dmpk at roche bioscience inc since  d  read more philip d worboys phd has served as our senior vice president translational science since march  where is he responsible for leading the progression of drug candidates from the discovery stage into human clinical studies including clinical pharmacology and biomarker development as well as project management previously dr worboys was vice president drug metabolism and pharmacokinetics dmpk since he joined theravance biopharma in october  from innoviva where he held the position of vice president dmpk since november  prior to joining innoviva he served as senior director dmpk at roche bioscience inc since  dr worboys was an associate director dmpk at pharmacia corporation from  until its acquisition by pfizer inc and was senior director dmpk at pfizer inc from  to  he spent the first part of his career in dmpk at merck sharp  dohme in harlow united kingdom and worked in various capacities at aventis unilever and glaxosmithkline prior to that dr worboys obtained his phd degree in pharmaceutics from manchester university united kingdom he holds a bsc degree in biochemistry from imperial college of science technology  medicine at the university of london source theravance biopharma inc on    sign up for equilar atlas and view philip d worboys phds full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like philip d worboys phd more specifically youll be able to identify corporate executives in philip d worboys phds network and community follow changes in philip d worboys phds employment and moneyinmotion connect with philip d worboys phd through your network of conections view full profile   search for over  executive profiles bio example philip d worboys phd philip d worboys phds connections  sign up now to view philip d worboys phds  connections » henrietta h fore board member exxon mobil corporation mathai mammen former employee innoviva inc rick e winningham chief executive officer and chairman of the board theravance biopharma inc renee d gala senior vice president chief financial officer and treasurer theravance biopharma inc frank pasqualone svp chief comm ops officer theravance biopharma inc dean j mitchell board member immunogen inc bradford j shafer executive vice president general counsel and secretary theravance biopharma inc peter s ringrose board member rigel pharmaceuticals inc susan m molineaux dir principal financial officer president and chief executive officer calithera biosciences sharathchandra s hegde senior vice president research theravance biopharma inc popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith carl g annessa evp and coo hornbeck offshore services inc elon r musk ceo and chairman tesla michael c montgomery board member nmi holdings inc × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login ï¿½  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   philip d worboys  senior vice president translational science at theravance biopharma inc news home advertising board and executive moves energy health care hedge funds m  a private equity technology you have    free profiles   left this month    start your free trial ➤ hey we noticed youre a relsci pro subscriber would you like to view the page there view on relsci pro ➤ email linkedin facebook google tweet reddit permalink philip d worboys senior vice president translational science at theravance biopharma inc overview relationships paths education career history public holdings philip d worboys senior vice president translational science at theravance biopharma inc overview age  born  number of relationships this person is connected to  people relationships see details rick winningham chief executive officer  chairman of the board at theravance biopharma inc kenneth r pitzer senior vice president product strategy  commercial planning at theravance biopharma inc renee d gala chief financial officer treasurer  senior vice president at theravance biopharma inc bradford j shafer secretary  executive vice presidentgeneral counsel at theravance biopharma inc dennis o driver vice president  chief human resources officer at theravance biopharma inc brett k haumann senior vice president clinical development  chief medical officer at theravance biopharma inc frank pasqualone senior vice president  chief commercial operations officer at theravance biopharma inc mathai mammen professional at merck  co inc heather m shane head west coast accelerator at california life sciences institute michael w aguiar president  chief executive officer at innoviva inc see  more listings with relsci professional start my free trial ➤ see  more paths to philip d worboys philip d worboys you connections via relationship science philip d worboys sync your contacts to see how you can connect with philip d worboys start my free trial ➤ see more educational background   the university of manchester the university of manchester uom is a large research university situated in the city of manchester england manchester university  as it is commonly known  is a public university formed in  by the merger of the university of manchester institute of science and technology est  and the victoria university of manchester est  manchester is a member of the worldwide universities research association group the russell group of british research universities and the n group the university of manchester is regarded as a red brick university and was a product of the civic university movement of the late th century it formed a constituent part of the federal victoria university between  when it received its royal charter and  when it was dissolved the main campus is south of manchester city centre on oxford road in  the university had around  students and  staff making it the largest singlesite university in the united kingdom the university of manchester had an income of £ million in – of which £ million was from research grants and contracts in the  research assessment exercise manchester came third in terms of research power and eighth for grade point average quality when including specialist institutions more students try to gain entry to the university of manchester than to any other university in the country with more than  applications for undergraduate courses according to the  highfliers report manchester is the most targeted university by the top  graduate employers in the  academic ranking of world universities manchester is ranked th in the world and th in the uk it is ranked th in the world and th in europe in the  times higher education world university rankings the university owns and operates major cultural assets such as the manchester museum whitworth art gallery john rylands library and jodrell bank observatory the university of manchester has  nobel laureates among its past and present students and staff the thirdhighest number of any single university in the united kingdom after cambridge and oxford four nobel laureates are currently among its staff – more than any other british university   imperial college london imperial college london officially the imperial college of science technology and medicine is a public research university located in london england specialising in science engineering medicine and business a former constituent college of the federal university of london it became fully independent on  july  as part of the celebrations of its centenary   university of london the university of london is a collegiate research university located in london england consisting of  constituent colleges  research institutes and a number of central bodies the nine largest institutions of the federal university usually termed the colleges are birkbeck goldsmiths kings college london the london business school queen mary royal holloway soas lse and ucl formerly a constituent college imperial college london left the university of london in  career history senior directordrug metabolism   current roche bioscience part of roche holding ag roche bioscience is a company headquartered in palo alto ca that discovers and develops prescription drugs senior vice president translational science current theravance biopharma inc theravance biopharma inc operates as a biopharmaceutical company which focuses on the discovery development and commercialization of small molecule medicines its products include telavancin under the vibativ brand revefenacin under the td  brand and neprilysin the company was founded on july  and is headquartered in george town cayman islands vice president drug metabolism  pharmacokinetics   prior innoviva inc theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies theravance is focused on the discovery development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease bacterial infections and central nervous system cnspain the companys key programs include relvar™ or breo™ ellipta™ffvi anoro™ ellipta™ umecvi and maba bifunctional muscarinic antagonistbeta agonist each partnered with glaxosmithkline plc and our oral peripheral mu opioid receptor antagonist program by leveraging its proprietary insight of multivalency to drug discovery theravance is pursuing a bestinclass strategy designed to discover superior medicines in areas of significant unmet medical need our objective is to discover develop and commercialize new medicines with superior efficacy convenience tolerability andor safety senior directormetabolism  pharmacokinetics    pfizer inc pfizer inc is a researchbased global biopharmaceutical company which engages in the manufacture of vaccines and injectable biologic medicines it operates through the following business segments global innovative pharmaceutical global vaccines oncology and consumer healthcare and global established pharmaceutical the global innovative pharmaceutical segment focuses on developing registering and commercializing novel value creating medicines that significantly improve patients lives the global vaccines oncology and consumer healthcare segment engages in the development and commercialization of vaccines and products for oncology and consumer healthcare the global established pharmaceutical segment includes the brands that have lost market exclusivity and generally the mature patentprotected products that are expected to lose exclusivity through  in most major markets and to a much smaller extent generic pharmaceuticals the company was founded by charles pfizer sr and charles erhart in  and is headquartered in new york ny associate directordmpk    pharmacia corporation pharmacia corp developed manufactured and marketed pharmaceutical products prescription pharmaceuticals included general therapeutics ophthalmology and hospital products including oncology and diversified therapeutics it also operated in consumer health care animal health diagnostics and contract manufacturing and bulk pharmaceutical chemicals the customers of the group were pharmacies hospitals chain warehouses governments physicians wholesalers and other distributors it was headquartered in peapack nj associate directordmpk prior pharmacia inc public holdings restricted data only for relsci professional users start my free trial ➤ see more other affiliations philip d worboys is affiliated with roche bioscience theravance biopharma inc innoviva inc pfizer inc pharmacia corporation pharmacia inc youve reached your  free profiles limit this month upgrade to relsci pro today to enjoy unlimited article views and much more start my free trial ➤ still not convinced check out our full listing of features here are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft worboys philip d  theravance biopharma insider transactions  tipranks go prologin  sign up follow✓get real time transactionsinsider detailsworboys philip dtheravance biopharma tbphsvp translational science not rankedworboys philip ds performanceworboys philip d has not reported any informative transactions and therefore cannot be rankedhow are insiders ranked insider holdings  theravance biopharma tbphmsee the top stocks by insiders  insider rolestheravance biopharma tbph svp translational sciencesee the top  corporate insiders  worboys philip ds trading historybased on form  follow✓get real time transactionscompany nameinsider positionholding valuelast transactionlast transaction amountlast transaction datetbphtheravance biopharmasvp translational scienceuninformative sellmay  worboys philip d has not reported any informative transactions for tbph therefore performance cannot be measured track record datetransactionamountno of sharesprice per shareprofitform  may   uninformative sell k   na feb   uninformative sell k   na feb   uninformative buy    na show moresee all insider trading from today you may also likemeet our smart portfolio see what top analysts say about your stocksget a breakdown of the different strategies based on detected insider trading activityfind the best performing analyst in each sector follow them so you never miss a recommendationrelated linkshow can i benefit from insider trading see the top  corporate insiders go to hot stocks by insiders find which stocks insiders traded today become a tipranks memberget the best investing tips  hacks straight to your emailfree membershipsubmitinsider trading daily newsletterprofessional daytrading strategy based on predictive insider transactionsannual return learn more powered by philip worboys facebook twitter  myspace on peekyou name username phone search by name please enter a first name please enter a last name location world usa alaskaalabamaarkansasarizonacaliforniacoloradoconnecticutwashington dcdelawarefloridageorgiahawaiiidahoillinoisindianaiowakansaskentuckylouisianamainemarylandmassachussetsmichiganminnesotamississippimissourimontananebraskanevadanew hampshirenew jerseynew mexiconew yorknorth carolinanorth dakotaohiooklahomaoregonpennsylvaniapuerto ricorhode islandsouth carolinasouth dakotatennesseetexasutahvermontvirginiawashingtonwest virginiawisconsinwyoming please enter the location search tools jump to social media public records phone email web search images  match for philip worboys country region city gender male female age                                                                                                                                                                                                        public records  background checks philip worboys  instant search view now free addresses phone numbers and social media links arrest records  driving infractions philip worboys search their arrest records driving records contact information photos and more phonebook we found philip worboys  philip worboyss phone  current address view all details  social media profiles  more  search free view all details philip worboyss phone  address  more view all details philip worboyss contact info social profiles  more view all details philip worboys  get contact information phone number philip worboys  reverse phone search  get photos  online profiles instantly phone number email addresses view philips hidden profiles on facebook and  networks philipgmail view philips hidden profiles on facebook and  networks philipyahoo view philips hidden profiles on facebook and  networks philiphotmail view philips hidden profiles on facebook and  networks philipaol view philips hidden profiles on facebook and  networks philipoutlook contact information  address history philip worboys discover philip worboyss address history phone age  more facebook twitter pinterest wikipedia instagram google linkedin foursquare music photo albums myspace documents web search images find out who called there was a time when a ringing phone was a mysterious beckoning one approached with bravery and cautious optimism most phones have been equipped wi… read more scroll